Quick Answer
Silo Pharma, Inc. reported Diluted EPS of $0.50 per share (loss) for fiscal year 2025.
Silo Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.50 | +58.0% |
| 2024 | -$1.19 | +0.8% |
| 2023 | -$1.20 | -3100.0% |
| 2021 | $0.04 | +180.0% |
| 2020 | -$0.05 | -150.0% |
| 2018 | -$0.02 | -300.0% |
| 2017 | $0.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +45.5% | +36.8% |
| June 30, 2025 | -$0.19 | +38.7% | +17.4% |
| March 31, 2025 | -$0.23 | +17.9% | -4.5% |
| September 30, 2024 | -$0.22 | -4.8% | +29.0% |
| June 30, 2024 | -$0.31 | +3.1% | -10.7% |
| March 31, 2024 | -$0.28 | +3.4% | -33.3% |
| September 30, 2023 | -$0.21 | — | +34.4% |
| June 30, 2023 | -$0.32 | — | -10.3% |
- Silo Pharma, Inc. showed an increase of +58.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, Silo Pharma, Inc.’s diluted eps has declined by 5100.0% (from $0.01 per share to $0.50 per share (loss)).
- The most recent figure is from Silo Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: